Literature DB >> 3896738

Temocillin in the treatment of gram-negative septicaemia.

H W Van Landuyt, A Lambert, A Van Couter, J Boelaert.   

Abstract

The effectiveness of temocillin in the treatment of culture-proven Gram-negative septicaemia was investigated in 22 adult patients, most of whom were elderly with serious underlying diseases. Administration of temocillin 2g twice daily to 15 patients or 1g twice daily to 7 patients resulted in clinical cure in 15 patients (68%), while 4 responded partially (18%) and 3 were considered failures (14%). The original pathogen was eradicated from 20 of 21 assessable patients (95%), 1 patient was unassessable and 1 was considered a failure. Superinfection was documented in 4 patients, originating twice in a central venous catheter, once in the urinary tract and once in an unidentified source. No clinical nor biological side effects were observed except for pain at the injection site in 1 patient who received the drug intramuscularly. We conclude that temocillin in monotherapy can be used effectively for proven Gram-negative septicaemia, and that the safety of the drug makes it particularly valuable in the elderly.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3896738     DOI: 10.2165/00003495-198500295-00039

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  6 in total

1.  Pharmacokinetics of temocillin (BRL 17421) in subjects with normal and impaired renal function.

Authors:  A Leroy; G Humbert; J P Fillastre; F Borsa; M Godin
Journal:  J Antimicrob Chemother       Date:  1983-07       Impact factor: 5.790

2.  BRL 17421, a novel beta-lactam antibiotic, highly resistant to beta-lactamases, giving high and prolonged serum levels in humans.

Authors:  B Slocombe; M J Basker; P H Bentley; J P Clayton; M Cole; K R Comber; R A Dixon; R A Edmondson; D Jackson; D J Merrikin; R Sutherland
Journal:  Antimicrob Agents Chemother       Date:  1981-07       Impact factor: 5.191

3.  The pharmacokinetics of temocillin in patients with normal and impaired renal function.

Authors:  J Boelaert; R Daneels; M Schurgers; A M Lambert; H W Van Landuyt; G Mellows; J Wolf; A J Swaisland
Journal:  J Antimicrob Chemother       Date:  1983-04       Impact factor: 5.790

4.  Comparative in vitro study of temocillin (BRL 17421), a new penicillin.

Authors:  R Bolivar; S S Weaver; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

5.  In vitro activity of temocillin (BRL 17421), a novel beta-lactamase-stable penicillin.

Authors:  L Verbist
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

6.  In vitro activity of temocillin (BRL 17421), a novel beta-lactam antibiotic.

Authors:  H W Van Landuyt; M Pyckavet; A Lambert; J Boelaert
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191

  6 in total
  1 in total

Review 1.  Penicillins. A current review of their clinical pharmacology and therapeutic use.

Authors:  Dilip Nathwani; Martin J Wood
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.